Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (111-120 of 204) with videos related to

Pageof 21
Sort By:
Blood Cells, Molecules & Diseases|September 19, 2009
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivoSelcuk Sozer, Takefumi Ishii, Maria Isabel Fiel, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2024
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor TherapyShivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, et al.
Blood|July 11, 2025
Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expressionLilian Varricchio, Gohar Mosoyan, Sebastian El Ghaity-Beckley, et al.
Experimental Hematology|May 18, 2004
Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cellsIl-Hoan Oh, Mary E Fabry, R Keith Humphries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasiaMargherita Massa, Vittorio Rosti, Isabella Ramajoli, et al.
Cancer Research|July 10, 2007
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosisJun Shi, Yan Zhao, Takefumi Ishii, et al.
Blood Advances|December 20, 2018
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53Bridget K Marcellino, Ronald Hoffman, Joseph Tripodi, et al.
Frontiers in Cell and Developmental Biology|January 1, 2021
Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of <i>ex vivo</i> Expanded Human Hematopoietic Stem CellsLuena Papa, Mansour Djedaini, Tiphaine C Martin, et al.
Blood|May 3, 2007
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosisStefan O Ciurea, Delwin Merchant, Nadim Mahmud, et al.
The Lancet. Haematology|December 31, 2021
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trialsGina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, et al.
Pageof 21

Showing results (111-120 of 204) with videos related to

Sort By:
Pageof 21
Blood Cells, Molecules & Diseases|September 19, 2009
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivoSelcuk Sozer, Takefumi Ishii, Maria Isabel Fiel, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2024
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor TherapyShivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, et al.
Blood|July 11, 2025
Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expressionLilian Varricchio, Gohar Mosoyan, Sebastian El Ghaity-Beckley, et al.
Experimental Hematology|May 18, 2004
Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cellsIl-Hoan Oh, Mary E Fabry, R Keith Humphries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasiaMargherita Massa, Vittorio Rosti, Isabella Ramajoli, et al.
Cancer Research|July 10, 2007
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosisJun Shi, Yan Zhao, Takefumi Ishii, et al.
Blood Advances|December 20, 2018
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53Bridget K Marcellino, Ronald Hoffman, Joseph Tripodi, et al.
Frontiers in Cell and Developmental Biology|January 1, 2021
Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of <i>ex vivo</i> Expanded Human Hematopoietic Stem CellsLuena Papa, Mansour Djedaini, Tiphaine C Martin, et al.
Blood|May 3, 2007
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosisStefan O Ciurea, Delwin Merchant, Nadim Mahmud, et al.
The Lancet. Haematology|December 31, 2021
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trialsGina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, et al.
Pageof 21